Cardinal Point Capital Management ULC
Position in GILD — Gilead Sciences, Inc.
CIK 1950841
TORONTO, A6
Position in GILD
as of Jun 30, 2026
· filed Jul 14, 2026
Position Value
$1,231,562
-$168,827 QoQ
Shares Held
9,748
-3.0% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.15%
of 13F equity value
Holder Rank
#988
of 2,266 holders
Holding Since
Mar 2025
6 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in GILD Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Cardinal Point Capital Management ULC holds $32,470,942 across 7 Drug Manufacturers - General names. GILD ranks #4 (3.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | JNJ |
Johnson & Johnson
|
72,763 | $18,479,619 | |
| 2 | PFE |
Pfizer Inc
|
332,062 | $7,996,052 | |
| 3 | ABBV |
AbbVie Inc.
|
8,437 | $2,123,086 | |
| 4 | GILD |
Gilead Sciences, Inc.
This page
|
9,748 | $1,231,562 | |
| 5 | LLY |
ELI LILLY & Co
|
1,008 | $1,209,025 | |
| 6 | MRK |
Merck & Co., Inc.
|
6,290 | $808,265 | |
| 7 | BMY |
Bristol Myers Squibb Co
|
10,818 | $623,333 |
All Filings in GILD
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,231,562 | 9,748 | Shares | Sole | 2026-07-14 | |
| 2026-03-31 | $1,400,389 | 10,048 | Shares | Sole | 2026-04-20 | |
| 2025-12-31 | $1,267,045 | 10,323 | Shares | Sole | 2026-02-05 | |
| 2025-09-30 | $1,201,353 | 10,823 | Shares | Sole | 2025-11-06 | |
| 2025-06-30 | $1,317,468 | 11,883 | Shares | Sole | 2025-07-31 | |
| 2025-03-31 | $1,339,893 | 11,958 | Shares | Sole | 2025-05-08 | |
| No filing history on record for this holder in this stock. | ||||||